William Blair Analysts Boost Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at William Blair increased their Q2 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research report issued on Monday, May 5th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($0.99) for the quarter, up from their prior estimate of ($1.31). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($3.35) EPS, Q1 2026 earnings at ($0.30) EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.60 EPS, Q4 2026 earnings at $1.27 EPS, FY2026 earnings at $1.64 EPS and FY2027 earnings at $12.93 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald restated an "overweight" rating and issued a $153.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. Robert W. Baird boosted their price objective on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a research report on Tuesday, May 6th. Bank of America raised their price target on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. HC Wainwright dropped their target price on shares of Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Royal Bank of Canada boosted their price target on Axsome Therapeutics from $190.00 to $193.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 29th. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $172.14.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock traded down $3.90 during mid-day trading on Thursday, reaching $106.26. 302,302 shares of the stock traded hands, compared to its average volume of 680,762. The business's 50-day moving average is $111.71 and its 200-day moving average is $104.84. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. The stock has a market capitalization of $5.23 billion, a PE ratio of -17.74 and a beta of 0.46. Axsome Therapeutics has a 12-month low of $64.11 and a 12-month high of $139.13.

Insider Activity at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at $5,529,450.09. The trade was a 6.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 22.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AXSM. Mutual of America Capital Management LLC grew its position in shares of Axsome Therapeutics by 0.3% during the first quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company's stock worth $4,621,000 after buying an additional 136 shares in the last quarter. Pitcairn Co. grew its position in shares of Axsome Therapeutics by 3.4% during the fourth quarter. Pitcairn Co. now owns 4,562 shares of the company's stock worth $386,000 after buying an additional 148 shares in the last quarter. Meridian Wealth Management LLC grew its position in shares of Axsome Therapeutics by 0.7% during the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock worth $1,791,000 after buying an additional 150 shares in the last quarter. Summit Investment Advisors Inc. grew its position in shares of Axsome Therapeutics by 4.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company's stock worth $326,000 after buying an additional 162 shares in the last quarter. Finally, Arizona State Retirement System grew its position in shares of Axsome Therapeutics by 1.8% during the fourth quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock worth $766,000 after buying an additional 164 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.